Dr. Shoko Takahashi of Shonan Beauty Clinic Shinjuku Main Hospital, which receives management support from SBC Medical Group Holdings Incorporated, headquartered in California, United States and led by CEO Yoshiyuki Aikawa, presented research findings at the international medical conference “AMWC Asia-TDAC 2026,” held in Taipei, Taiwan, over three days from Friday, May 1, 2026. AMWC Asia-TDAC is an international academic conference jointly held by Aesthetic Medicine World Congress (AMWC), one of the world’s largest international conferences in aesthetic medicine and dermatology, and the Taiwan Dermatology Aesthetic Conference (TDAC), organized by the Taiwanese dermatology community. Specialists and researchers in dermatology and aesthetic medicine from across Asia and around the world gather to share the latest treatment technologies and clinical insights. At AMWC Asia-TDAC 2026, Dr. Takahashi gave a presentation titled “Strategic use of injectable collagen for periorbital rejuvenation.” The periorbital area is a region where age-related skin thinning and collagen loss are especially visible, and delicate approaches using collagen formulations have attracted growing international attention in recent years. Dr. Takahashi shared practical insights on strategically applying the latest collagen injection techniques to periorbital rejuvenation treatment. Her presentation drew strong interest from physicians and researchers from various countries for its potential to improve treatment safety and efficiency while contributing to a more reassuring medical experience. In recent years, technological innovation has advanced rapidly in the field of aesthetic medicine, increasing the importance of knowledge sharing and academic collaboration beyond clinical practice. To respond to diversifying needs, the introduction of cutting-edge technologies must be accompanied by a broad perspective and flexible thinking. SBC Medical Group will continue to promote advanced initiatives throu